Since combined blockade of ILT4 and PD-L1 showed a synergistic effect on tumor inhibition in vitro, we explored whether combination therapy could increase ICI treatment potential in EGFR wild-type NSCLC in vivo. This evidence concerns the gene CD274 and neoplasm.